Agios Pharmaceuticals’ Post

⏳ The countdown is on for Wilson Sonsini’s Inaugural Biotech Summit in Boston, October 9-10! ⌛ HIC's CEO and Principal Regulatory Advisor, Deb Autor, will share insights on FDA hot topics and regulatory trends alongside fellow industry leaders. Why attend? 👥 Connect with influential and knowledgeable leaders at the intersection of biotech, venture capital, and policy. ✍ Learn about regulatory trends, antitrust issues, and strategic collaborations that drive innovation in medical therapies. 🗣 Engage in topics that will highlight ways to leverage AI in healthcare. You don't want to miss this event! #BiotechSummit #FDA #Biotech #Boston #WilsonSonsini #Innovation #MedTech #PharmaBiotech #Regulatory

At Goodland Pharma, our journey began with a profound passion for the triumphs of life science. Founded by visionaries deeply entrenched in the industry, we've cultivated global teams that have played pivotal roles in countless scientific breakthroughs. What sets us apart? Our seasoned expertise isn't just surface-level – it delves deep into your world, comprehending the intricate nuances of regulations and the critical factors that drive clinical trial success. Get started here: https://lnkd.in/g_z8FmWD #GoodlandPharma #TailoredSolutions #LifeScience #ClinicalTrials

Learn how to overcome post-approval challenges and successfully expand into new markets with these expert insights.

In our winter #lifesciences outlook, we examine: ⇛ Easing funding concerns for #biotechs ⇛ Global clinical trial challenges ⇛ Resilient revenue trends for #medtech

‘Navigating the Biopharma Services Lanscape: Current Trends and Future Perspectives’ at BIO-Europe - interesting discussions regarding price vs value in service providers. Speed, flexibility, dependability and quality are key considerations when delivering novel molecules to the clinic, not just cost, and a track record of delivering success commands a premium Sygnature Discovery #BioEurope

The wait is over! Fierce Biotech Fierce 15 is here! Nominations starting today in search of the best and brightest in biotech.  Send in your suggestions for the fiercest companies in the game now! 👉 https://lnkd.in/eMqebHWa 📢 Follow Fierce Life Sciences Events for the latest news and updates #FierceBiotech #FiercePharma #Fierce15

In our winter #lifesciences outlook, we examine: ⇛ Easing funding concerns for #biotechs ⇛ Global clinical trial challenges ⇛ Resilient revenue trends for #medtech

Bicoll offers unique expertise in plant processing. This can be used for different indications in the discovery of novel chemical entities. Within a few weeks, you can come up with a biologically active compound class binding to your target. The proprietary technology has been successfully proven over the course of 25 years. Learn more about how to enhance and improve your success rate in preclinical development. #biotech #success #pharma #drugdiscovery #biologicallyactive #botechgate #digitalpartnering

In our winter #lifesciences outlook, we examine: ⇛ Easing funding concerns for #biotechs ⇛ Global clinical trial challenges ⇛ Resilient revenue trends for #medtech

Dear colleagues, dear friends, For new commercial-stage Biotech companies – with the US launch coming up or fully underway – sooner than later an urgent question occurs: “How can we maintain revenue growth once our new product reaches its sales plateau in the US market?” Over the past months, our consulting team had many discussions with new commercial-stage US Biotech companies and ran several analyses re. the commercial and financial feasibility of a European market entry: > Licensing-out for Europe is the most often favored option by new commercial-stage US Biotechs > Licensing-out for Europe is in many analysis cases NOT the best option for new commercial-stage US Biotechs > Complexity of European Market Access regulations and Willingness-to-Pay are perceived as major hurdles for pursuing the European market opportunity > Funding of a European market entry (or expansion) is regarded as a major challenge, due to the resource requirements of the initial US Launch > Finding & integrating the necessary (un-biased) expertise (Market Access, Pricing & Reimbursement, Business Model & Go-to-Market, Commercial & Financial Analysis) is difficult and challenging > Entering the European market can offer significant incremental revenue streams & company growth mid- to long-term Based on six defined Strategic Options for a potential European market entry (or expansion), we have developed “The Bridge”, a concept with a structured process and tailored proprietary analytical tools, to analyze and conclude on the optimal European Strategy: from “Out-licensing” to “Market yourself” to “Out-sourcing” to “No entry at all”. Our initial "Financial Acid Test" (FAT), a focused 3-week analysis, will provide first important insights re. the commercial feasibility of a new product for the European market – helping to decide whether or not to move forward with an in-depth analysis of the opportunities, strategies and operational requirements of a potential expansion into the European market. More information about FAT can be found at: 1d3d0b_ca2f470151f4444e8d275ec25d29c089.pdf (bridgeforgrowth.com) Please don’t hesitate to share this post with anyone who might be interested. Greetings, Tom